ALGS · Aligos Therapeutics, Inc.
$6.93
-0.14 (-1.98%)
At close · Aug 28
Going-concern doubt
— cleared Aug 6, 2026
The latest filing no longer states the doubt (first flagged May 7, 2026).
View the 10-Q filed Aug 6, 2026Market Cap
$26.95M
Shares
3.59M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Lawrence M. Blatt | Ph.D., M.B.A. President and Chief Executive Officer | $4,057,234 |
| Lesley Ann Calhoun | Executive Vice President, Chief Operating Officer and Chief Financial Officer | $1,579,689 |
| Julian A. Symons | D.Phil. Executive Vice President, Chief Scientific Officer | $1,078,522 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Lawrence M. Blatt | Ph.D., M.B.A. President and Chief Executive Officer | $2,135,283 |
| Lesley Ann Calhoun | Executive Vice President, Chief Operating Officer and Chief Financial Officer | $1,019,746 |
| Julian A. Symons | D.Phil. Executive Vice President, Chief Scientific Officer | $834,517 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Lawrence M. Blatt | Ph.D., M.B.A. President and Chief Executive Officer | $1,344,458 |
| Leonid Beigelman | Former President | $955,127 |
| Matthew W. McClure | Executive Vice President, Chief Medical Officer | $837,724 |
| Julian A. Symons | D.Phil. Executive Vice President, Chief Scientific Officer | $836,319 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lawrence M. Blatt | President and Chief Executive Officer | $1,851,128 |
| Leonid Beigelman | Former President | $1,378,244 |
| Julian A. Symons | D.Phil. Executive Vice President, Chief Scientific Officer | $946,850 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Lawrence M. Blatt | Ph.D., Chief Executive Officer | $872,582 |
| Leonid Beigelman | Ph.D., President | $702,253 |
| Julian A. Symons | D.Phil., Executive Vice President, Chief Scientific Officer | $618,822 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lawrence M. Blatt | Ph.D., Chief Executive Officer | $7,400,702 |
| Leonid Beigelman | Ph.D., President | $4,420,192 |
| Julian A. Symons | D.Phil. Executive Vice President, Chief Scientific Officer | $2,828,343 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Lawrence M. Blatt | Ph.D., Chief Executive Officer | $674,366 |
| Leonid Beigelman | Ph.D., President | $554,957 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Carole Nuechterlein, J.D. | Class III director | Appointed | 2026-06-26 |
| Bridget Martell, M.A., M.D. | Class III director | Appointed | 2026-06-26 |
| Nikhil Aneja | Principal Accounting Officer | Appointed | 2026-02-04 |
| Margarita Chavez | Class II director | Appointed | 2025-06-26 |
| Heather Preston, M.D. | Class II director | Appointed | 2025-06-26 |
| K. Peter Hirth, Ph.D. | Class II director | Appointed | 2025-06-26 |
| Lesley Ann Calhoun | Chief Operating Officer | Appointed | 2025-02-03 |
| Margarita Chavez, J.D. | Class II director | Appointed | 2024-08-08 |
| Heather Preston, M.D. | Class II director | Appointed | 2024-08-08 |
| Jack Nielsen | member of the board of directors | Resigned | 2024-05-22 |
| Matthew McClure | Chief Medical Officer | Resigned | 2024-05-15 |
| Leonid Beigelman | President | Resigned | 2023-11-22 |
| Leonid Beigelman | President | Resigned | 2023-11-15 |
| Leonid Beigelman | Board of Directors | Resigned | 2023-11-15 |
| Bridget Martell, M.D. | Class III director | Appointed | 2021-11-18 |
| James Scopa | Class I director | Appointed | 2021-04-27 |
Key facts
CIK
1799448
CUSIP
01626L204
13F (30d)
28 filings
28 filers
Visit website
Investor relations